Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Epizyme Inc (EPZM)

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,903,989
  • Shares Outstanding, K 101,061
  • Annual Sales, $ 23,800 K
  • Annual Income, $ -170,300 K
  • 60-Month Beta 2.06
  • Price/Sales 80.76
  • Price/Cash Flow N/A
  • Price/Book 6.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.56
  • Number of Estimates 7
  • High Estimate -0.53
  • Low Estimate -0.63
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -5.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.19 +24.03%
on 05/01/20
19.76 -4.66%
on 05/27/20
+1.36 (+7.78%)
since 04/27/20
3-Month
13.50 +39.56%
on 04/02/20
23.61 -20.20%
on 03/05/20
-1.63 (-7.96%)
since 02/27/20
52-Week
9.73 +93.63%
on 10/09/19
27.82 -32.28%
on 01/21/20
+5.91 (+45.71%)
since 05/24/19

Most Recent Stories

More News
Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions

Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

EPZM : 18.84 (-0.95%)
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that multiple abstracts have been accepted for poster...

EPZM : 18.84 (-0.95%)
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses

Allogene (ALLO) reports no revenues for the first quarter of 2020.

IMMU : 33.50 (-1.96%)
SGEN : 151.77 (-0.79%)
EPZM : 18.84 (-0.95%)
ALLO : 50.00 (+2.06%)
Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss

Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.

PFE : 37.74 (+0.88%)
MRK : 78.29 (+0.95%)
NVS : 84.87 (+0.50%)
EPZM : 18.84 (-0.95%)
Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

EPZM : 18.84 (-0.95%)
Epizyme: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Monday reported a loss of $50.9 million in its first quarter.

EPZM : 18.84 (-0.95%)
Epizyme Reports Business Progress and First Quarter 2020 Financial Results

--Business Continuity Plans in Place in Response to COVID-19

EPZM : 18.84 (-0.95%)
Earnings Preview: Epizyme (EPZM) Q1 Earnings Expected to Decline

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EPZM : 18.84 (-0.95%)
Epizyme Announces Date of First Quarter 2020 Financial Results

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast...

EPZM : 18.84 (-0.95%)
Relatively Good Performance Detected in Shares of Novavax Inc in the Biotechnology Industry (NVAX , EPZM , LJPC , FLXN , ESPR )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

EPZM : 18.84 (-0.95%)
LJPC : 5.19 (+3.18%)
NVAX : 46.90 (+3.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 20.47
1st Resistance Point 19.66
Last Price 18.84
1st Support Level 18.13
2nd Support Level 17.42

See More

52-Week High 27.82
Fibonacci 61.8% 20.91
Last Price 18.84
Fibonacci 50% 18.77
Fibonacci 38.2% 16.64
52-Week Low 9.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar